References
- Mellin G. W., Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy with case reports of congenital anomalies. N Engl J Med 1962; 267: 1184–93
- Somers G. F. Pharmacological properties of thalidomide (alpha‐phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother 1960; 15: 111–16
- Tseng S., Pak G., Washenik K., Pomeranz M. K., Shupack J. L. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969–79
- Stirling D. I. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998; 17: 231–42
- Mellin G. W. The saga of thalidomide. N Engl J Med 1962; 267: 1238–44
- Jew L. J. Thalidomide in erythema nodosum leprosum. Ann Pharmacother 1990; 24: 482–3
- Wines N. Y., Cooper A. J., Wines M. P. Thalidomide in dermatology. Australas J Dermatol 2002; 43: 229–40
- Faure M., Thivolet J., Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 275–80
- Barnhill R. L., Doll N. J., Millikan L. E., Hastings R. C. Studies on the anti‐inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11: 814–19
- Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699–703
- McHugh S. M., Rifkin I. R., Deighton J., Wilson A. B., Lachmann P. J., Lockwood C. M., et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160–7
- Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326–8
- Hasper M. F., Klokke A. H. Thalidomide in the treatment of chronic discoid lupus erythematosus. Acta Derm Venereol 1982; 62: 321–4
- Naafs B., Barkers E. J. M., Flinterman J., Fabbr W. R. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982; 107: 83–6
- Bahmer F. A., Zaun H., Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol 1982; 62: 449–50
- Sharma N. L., Sharma V., Shanker V., Mahajan V. K., Sarin S. Deep vein thrombosis: A rare complication of thalidomide therapy in recurrent erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 2004; 72: 483–5
- Moreira A. L., Friedlander D. R., Shif B., Kaplan G., Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neuro Oncology 1999; 43: 109–14
- Flageul B., Wallach D., Cavelier‐Balloy B., Bachelez H., Carsuzaa F., Dubertret L. Thalidomide and thrombosis. Ann Dermatol Venerol. 2000; 127: 171–4
- Ochonisky S., Verroust J., Bastuji‐Garin S., Gheradi R., Revuz J. Thalidomide neuropathy incidence and clinico‐electrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66–9
- Sharma N. L., Mahajan V. K., Sharma V. C., Sarin S., Sharma R. C. Erythema nodosum leprosum and HIV infection: A therapeutic experience. Int J Leprosy Other Mycobact Dis 2005; 73: 189–93